<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02203357</url>
  </required_header>
  <id_info>
    <org_study_id>HepB-2014</org_study_id>
    <nct_id>NCT02203357</nct_id>
  </id_info>
  <brief_title>A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults</brief_title>
  <official_title>A Randomized, Opened, Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Young Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangxi Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liuzhou City Center for disease control and prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen Kangtai Biological Products Co., LTD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the immunogenicity and Anti-HBV antibody
      persistence of hepatitis B vaccine with different doses and schedules. Hepatitis B vaccine
      with the regimens of 20μg, 0-1-6 mon and 60μg,0-1 or 0-2 mon will be administered to young
      adults, and the comparative immunogenicity among the three groups will be measured at 1 mon
      post-a series vaccination, 1- and 2-year after the first dose of the regimen. Furthermore,
      the safety of hepatitis B vaccine with different doses and schedules will also be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>immunogenicity of hepatitis B vaccine with different doses and schedules in healthy young adults</measure>
    <time_frame>one month after a series vaccination of the regimen</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>immunogenicity of hepatitis B vaccine with different doses and schedules in healthy young adults</measure>
    <time_frame>1-year after the first dose of the regimens</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immunogenicity of hepatitis B vaccine with different doses and schedules in healthy young adults</measure>
    <time_frame>2-year after the first dose of the regimens</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>safety of HBV vaccine with different doses and schedules in health young adults</measure>
    <time_frame>0-3 day after every dose of immunization</time_frame>
    <description>Number of participants with adverse events as a measure of safety and tolerability</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">354</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>20μg, 0-1-6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>117 young adults were administered with 20μg of hepatitis B vaccine according to the 0-1-6 mon schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60μg, 0-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>112 young adults were asministered with 60μg of hepatitis B vaccine according to the 0-1 mon schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60μg, 0-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>125 young adults were asministered with 60μg of hepatitis B vaccine according to the 0-2 mon schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis B vaccine</intervention_name>
    <description>Hepatitis B vaccine, 60 μg/1ml recombinant hepatitis B vaccine,20 μg/1ml recombinant hepatitis B vaccine, Shenzhen Kangtai Biological Products Co, LTD.</description>
    <arm_group_label>20μg, 0-1-6</arm_group_label>
    <arm_group_label>60μg, 0-1</arm_group_label>
    <arm_group_label>60μg, 0-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects aged between 16 and 25 as established by medical history and clinical
             examination

          -  Written informed consent will be obtained from each subject before the serum screening
             of HBV markers

          -  Seronegative for HBsAg, anti-HBs antibody, anti-HBc antibody

          -  Have never been immunized with HBV vaccine before

        Exclusion Criteria:

          -  Subject has a medical history of allergic to any ingredient of vaccine

          -  Family history of seizures or progressive neurological disease

          -  Autoimmune disease or immunodeficiency

          -  Women with pregnant

          -  Bleeding disorder diagnosed by a doctor

          -  Chronic diseases: hepatitis, tumor, tuberculosis,et.al

          -  Any prior administration of immunoglobulins or blood products in the last 3 mon before
             recruitment

          -  Subjects had a medical history of serious adverse reactions to vaccines
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xueen Liu, Dr.</last_name>
    <phone>86-10-82802413</phone>
    <email>xueenliu@bjmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xueen Liu, Dr.</last_name>
      <phone>86-10-82802413</phone>
      <email>xueenliu@bjmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Lin Wei, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xueen Liu, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2014</study_first_submitted>
  <study_first_submitted_qc>July 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2014</study_first_posted>
  <last_update_submitted>October 27, 2015</last_update_submitted>
  <last_update_submitted_qc>October 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Xueen Liu</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>hepatitis B</keyword>
  <keyword>hepatitis B vaccine</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

